Gastrointestinal Cancers With Peritoneal Carcinomatosis: Surgery and Hyperthermic Intraperitoneal Chemotherapy

Brian W. Loggie, Peter Thomas

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

This review focuses on the underlying rationale for the use of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS+HIPEC) in the treatment of patients with primary gastrointestinal tumors with metastatic peritoneal disease. It examines the advantages of CS+HIPEC in peritoneal cancers and explores the controversies surrounding this treatment. For low-grade cancers, such as pseudomyxoma peritonei, CS+HIPEC is standard of care. However, for more aggressive tumors, such as gastric cancers, the results with this approach are not as encouraging and patient selection is very important. Generally, the cost of HIPEC is not prohibitive and increases the cost of surgery by only a small percentage. Overall, the consensus is that HIPEC is probably beneficial for less aggressive cancers. We believe that CS+HIPEC should be standard of care for appendiceal and colorectal cancers with peritoneal disease. For other cancers, such as gastric, pancreatic, or small bowel cancers, further study is warranted.

Original languageEnglish (US)
Pages (from-to)515-521
Number of pages7
JournalOncology (Williston Park, N.Y.)
Volume29
Issue number7
StatePublished - Jul 1 2015

Fingerprint

Gastrointestinal Neoplasms
Carcinoma
Drug Therapy
Peritoneal Diseases
Neoplasms
Standard of Care
Appendiceal Neoplasms
Pseudomyxoma Peritonei
Intestinal Neoplasms
Costs and Cost Analysis
Patient Selection
Stomach Neoplasms
Colorectal Neoplasms
Stomach
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Gastrointestinal Cancers With Peritoneal Carcinomatosis : Surgery and Hyperthermic Intraperitoneal Chemotherapy. / Loggie, Brian W.; Thomas, Peter.

In: Oncology (Williston Park, N.Y.), Vol. 29, No. 7, 01.07.2015, p. 515-521.

Research output: Contribution to journalReview article

@article{e7865914e3a742d78291c1f6d45f7c3e,
title = "Gastrointestinal Cancers With Peritoneal Carcinomatosis: Surgery and Hyperthermic Intraperitoneal Chemotherapy",
abstract = "This review focuses on the underlying rationale for the use of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS+HIPEC) in the treatment of patients with primary gastrointestinal tumors with metastatic peritoneal disease. It examines the advantages of CS+HIPEC in peritoneal cancers and explores the controversies surrounding this treatment. For low-grade cancers, such as pseudomyxoma peritonei, CS+HIPEC is standard of care. However, for more aggressive tumors, such as gastric cancers, the results with this approach are not as encouraging and patient selection is very important. Generally, the cost of HIPEC is not prohibitive and increases the cost of surgery by only a small percentage. Overall, the consensus is that HIPEC is probably beneficial for less aggressive cancers. We believe that CS+HIPEC should be standard of care for appendiceal and colorectal cancers with peritoneal disease. For other cancers, such as gastric, pancreatic, or small bowel cancers, further study is warranted.",
author = "Loggie, {Brian W.} and Peter Thomas",
year = "2015",
month = "7",
day = "1",
language = "English (US)",
volume = "29",
pages = "515--521",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "7",

}

TY - JOUR

T1 - Gastrointestinal Cancers With Peritoneal Carcinomatosis

T2 - Surgery and Hyperthermic Intraperitoneal Chemotherapy

AU - Loggie, Brian W.

AU - Thomas, Peter

PY - 2015/7/1

Y1 - 2015/7/1

N2 - This review focuses on the underlying rationale for the use of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS+HIPEC) in the treatment of patients with primary gastrointestinal tumors with metastatic peritoneal disease. It examines the advantages of CS+HIPEC in peritoneal cancers and explores the controversies surrounding this treatment. For low-grade cancers, such as pseudomyxoma peritonei, CS+HIPEC is standard of care. However, for more aggressive tumors, such as gastric cancers, the results with this approach are not as encouraging and patient selection is very important. Generally, the cost of HIPEC is not prohibitive and increases the cost of surgery by only a small percentage. Overall, the consensus is that HIPEC is probably beneficial for less aggressive cancers. We believe that CS+HIPEC should be standard of care for appendiceal and colorectal cancers with peritoneal disease. For other cancers, such as gastric, pancreatic, or small bowel cancers, further study is warranted.

AB - This review focuses on the underlying rationale for the use of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS+HIPEC) in the treatment of patients with primary gastrointestinal tumors with metastatic peritoneal disease. It examines the advantages of CS+HIPEC in peritoneal cancers and explores the controversies surrounding this treatment. For low-grade cancers, such as pseudomyxoma peritonei, CS+HIPEC is standard of care. However, for more aggressive tumors, such as gastric cancers, the results with this approach are not as encouraging and patient selection is very important. Generally, the cost of HIPEC is not prohibitive and increases the cost of surgery by only a small percentage. Overall, the consensus is that HIPEC is probably beneficial for less aggressive cancers. We believe that CS+HIPEC should be standard of care for appendiceal and colorectal cancers with peritoneal disease. For other cancers, such as gastric, pancreatic, or small bowel cancers, further study is warranted.

UR - http://www.scopus.com/inward/record.url?scp=85047581080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047581080&partnerID=8YFLogxK

M3 - Review article

C2 - 26178339

AN - SCOPUS:85047581080

VL - 29

SP - 515

EP - 521

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 7

ER -